This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma.
SparkCures ID | 836 |
---|---|
Trial Phase | Phase 2 |
Enrollment | 8 Patients |
Treatments |
|
Tags | |
Trial Sponsors |
|
Trial Collaborators |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View Centers